Clinical trial NCT03828682: Veloxis de Novo Kidney Transplant ECSWD
Official title: A 12-Month, Open Label Study of Extended Release Tacrolimus (Envarsus XR®, LCPT) With Mycophenolate, Rabbit Antithymocyte Globulin (rATG) and Early Steroid Withdrawal in de Novo Kidney Transplant Recipients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Kidney Transplantation
Immunosuppression
Keywords: tacrolimus
extended release
kidney transplantation
steroid withdrawal
once daily
Lead sponsor: University of Cincinnati
Sponsor class: OTHER
Collaborators: name: Veloxis Pharmaceuticals
First posted: 2019-02-04
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A prospective cohort of de novo kidney transplant recipients will be assigned to treatment group and compared to historical controls
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate the safety and efficacy of LCPT in combination with rATG, mycophenolate and early corticosteroid withdrawal (CSWD) in de novo kidney transplant recipients.


Eligibility criteria: Inclusion Criteria:

1. Male and female patients ≥ 18 years of age.
2. Patient who is receiving a renal transplant from a living or heart-beating deceased donor.
3. Female patients of child bearing potential must have a negative urine or serum pregnancy test within the past 48 hours prior to study inclusion.
4. The patient has given written informed consent to participate in the study

Exclusion Criteria:

1. Patient has previously received an organ transplant other than a kidney.
2. Patient is receiving an HLA identical living donor transplant.
3. Patient who is a recipient of a multiple organ transplant.
4. Patient has a most recent cytotoxic PRA of \>25% or calculated PRA \>50% where multiple moderate level HLA antibodies exist and in the opinion of the PI represents substantial HLA sensitization.
5. Patient with a positive T or B cell crossmatch that is primarily due to HLA antibodies.
6. Patient with a donor specific antibody (DSA) as deemed by the PI to be associated with significant risk of rejection.
7. Patient has received an ABO incompatible donor kidney.
8. The deceased donor and/or deceased donor kidney meet any of the following extended criteria for organ donation (ECD):

   1. Donor age ≥ 60 years OR
   2. Donor age 50-59 years and 1 of the following:

   i. Cerebrovascular accident (CVA) + hypertension + SCr \> 1.5 mg/dL OR ii. CVA + hypertension OR iii. CVA + SCr \> 1.5 mg/dL OR iv. Hypertension + SCr \> 1.5 mg/dL OR c. CIT ≥ 24 hours, donor age \> 10 years OR d. Donation after cardiac death (DCD)
9. Recipients will be receiving a dual or en bloc kidney transplant.
10. Donor anticipated cold ischemia is \>30hours.
11. Recipient that is seropositive for hepatitis C virus (HCV) with detectable Hepatitis C viral load are excluded. HCV seropositive patients with a negative HCV viral load testing may be included.
12. Recipients with a positive hepatitis B viral load or positive hepatitis B surface antigen testing within 1 year of consent.
13. Hepatitis B surface antibody negative recipients receiving a kidney from a donor seropositive for hepatitis B core antibody or hepatitis B nucleic acid.
14. Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV).
15. Recipient who is seronegative for Epstein Barr Virus (EBV)
16. Patient has uncontrolled concomitant infection or any other unstable medical condition that could interfere with the study objectives.
17. Patients with thrombocytopenia (PLT \<75,000/mm3), and/or leukopenia (WBC \< 2,000/mm3), or anemia (hemoglobin \< 6 g/dL) prior to study inclusion.
18. Patient is taking or has been taking an investigational drug in the 30 days prior to transplant.
19. Patient who has undergone desensitization therapy within 6 months prior to transplant.
20. Patient has a known hypersensitivity to tacrolimus, mycophenolate mofetil/mycophenolic acid, rabbit anti-thymocyte globulin, or glucocorticoids.
21. Patient is receiving chronic steroid therapy at the time of transplant.
22. Patients with a history of cancer (other than non-melanoma skin cell cancers cured by local resection) within the last 5 years, unless they have an expected disease free survival of \>95%.
23. Patient is pregnant, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by positive human Chorionic Gonadotropin (hCG) laboratory test.
24. Women of childbearing potential must use reliable contraception simultaneously, unless they are status post bilateral tubal ligation, bilateral oophorectomy, or hysterectomy.
25. Patient has any form of substance abuse, psychiatric disorder or a condition that, in the opinion of the investigator, may invalidate communication with the investigator.
26. Inability to cooperate or communicate with the investigator.
27. Renal allograft has been reperfused for more than 48 hours at the time of enrollment
28. Patient unable to receive intact LCPT formulation

Primary outcomes:
measure: Proportion of patients with the combination oral outcome of Biopsy-proven acute rejection, patient death and graft loss
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: The Christ Hospital
state: Ohio
city: Cincinnati
country: United States
facility: University of Cincinnati
state: Ohio
Study officials:
affiliation: University of Cincinnati
name: Simon Tremblay, PharmD, PhD
role: PRINCIPAL_INVESTIGATOR
References: